David Ouyang

I am a cardiologist and researcher in the Division of Research at Kaiser Permanente Northern California and an adjunct Assistant Professor at the Smidt Heart Institute at Cedars-Sinai. I majored in statistics at Rice University, obtained my MD at UCSF, and received post-graduate medical education in internal medicine, cardiology, and a postdoc in computer science and biomedical data science at Stanford University. I am also a Deputy Editor at NEJM AI, Chair of the ImageGuideRegistry for the American Society of Echocardiography, and a co-founder of InVision Medical Technology.

Our mission is to improve cardiovascular diagnosis and disease detection using computer vision and artificial intelligence. We focus on three pillars: AI model development (precision phenotyping), AI model understanding (interpretable medical AI), and AI model deployment (clinical trials). Our work has been published in Nature, Nature Medicine, NEJM AI, Circulation, JAMA Cardiology, and the European Heart Journal. We conducted the first blinded, randomized trial of AI in cardiology, and our echocardiography models are now FDA-cleared and deployed in clinical care.

The best part of the job are the people I get to work with. I have the good fortune of working with a great group of motivated, talented, and creative individuals from a wide range of backgrounds. Our lab members bring expertise from a wide range of backgrounds ranging from physics, mechanical engineering, data science, math, and computer science to cardiology, anesthesia, and internal medicine.

If you're interested in improving cardiovascular imaging and cardiovascular care, please email me!

A selection of papers below. For the full list, see the complete publications page.

• Vukadinovic M, Chiu I-M, Tang X, Yuan N, Chen T-Y, Cheng P, Li D, Cheng S, He B, Ouyang D. "Comprehensive echocardiogram evaluation with view primed vision language AI." Nature.
• He B, Kwan AC, Cho JH, Yuan N, Pollick C, Shiota T, Ebinger J, Bello NA, Wei J, Josan K, Duffy G, Jujjavarapu M, Siegel R, Cheng S, Zou JY, Ouyang D. "Blinded, Randomized Controlled Trial of Sonographer vs. Artificial Intelligence Assessment of Cardiac Function." Nature.
• Ouyang D, He B, Ghorbani A, Langlotz CP, Heidenreich PA, Harrington RA, Liang DH, Ashley EA, Zou JY. "Video-based artificial intelligence for beat-to-beat assessment of cardiac function." Nature.
• Christensen M, Vukadinovic M, Yuan N, Ouyang D. "Vision–language foundation model for echocardiogram interpretation." Nature Medicine.
• Wu E, Wu K, Daneshjou R, Ouyang D, Ho D, Zou JY. "How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals." Nature Medicine.
• Vrudhula A, Duffy G, Vukadinovic M, Liang D, Cheng S, Ouyang D. "High Throughput Deep Learning Detection of Mitral Regurgitation." Circulation.
• Duffy G*, Cheng PP*, Yuan*, He B, Kwan AC, Shun-Shin MJ, Alexander KM, Ebinger J, Lungren MP, Rader F, Liang DH, Schnittger I, Ashley EA, Zou JY, Patel J, Witteles R, Cheng S, Ouyang D. "High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning." JAMA Cardiology.
• Sahashi Y, Vukadinovic M, Amrollahi F, Trivedi H, Rhee J, Chen JH, Cheng S, Ouyang D, Kwan AC. "Opportunistic Screening of Chronic Liver Disease with Deep Learning Enhanced Echocardiography." NEJM AI.

See the complete list of publications, or browse Google Scholar.

I am a co-founder of InVision Medical Technology, a Y Combinator–backed company building FDA-cleared AI for echocardiography — the path by which our research models reach routine clinical care.

• Precision LVEF — FDA 510(k) cleared (2024, K232331); AI ejection-fraction measurement validated in a blinded, randomized trial.
• Precision Cardiac Amyloid — FDA 510(k) cleared (2025, K243866), with FDA Breakthrough Device designation (2024).
• Medicare reimbursement — CMS New Technology Add-on Payment for Precision Cardiac Amyloid, up to $2,275 per inpatient stay, effective October 2026.
• Precision Cirrhosis — FDA Breakthrough Device designation for AI detection of end-stage liver disease from echocardiography.